Futura Medical PLC Exercise of Warrants (3898C)
12 Junio 2023 - 2:23AM
UK Regulatory
TIDMFUM
RNS Number : 3898C
Futura Medical PLC
12 June 2023
12 June 2023
Futura Medical plc
("Futura" or the "Company")
Exercise of Warrants, Issue of Equity and Total Voting
Rights
Futura Medical plc (AIM: FUM), a pharmaceutical company
developing a portfolio of innovative products based on its
proprietary, transdermal DermaSys(R) drug delivery technology and
currently focused on sexual health and pain, announces that it has
today received a warrant exercise notice (the "Notice") from
Lombard Odier Asset Management (Europe) Limited ("Lombard Odier")
in respect of 10,937,500 ordinary shares of 0.2 pence in the
Company ("Ordinary Shares"), with an exercise price of 40 pence per
share. The Notice is in respect of all warrants previously held by
Lombard Odier. Proceeds of GBP4,375,000 will be received by the
Company in respect of the warrant exercise.
Application will be made for the 10,937,500 Ordinary Shares to
be admitted to trading on AIM ("Admission") and it is expected that
Admission will occur on or around 16 June 2023.
Total voting rights
Following Admission, the Company's enlarged issued share capital
will comprise 299,071,457 Ordinary Shares, with one voting right
per share. The Company does not hold any Ordinary Shares in
treasury and therefore the total number of Ordinary Shares with
voting rights in the Company is 299,071,457.
The above figure of 299,071,457 may be used by shareholders as
the denominator for the calculations by which they will determine
if they are required to notify their interest in, or a change to
their interest in, the share capital of the Company under the FCA's
Disclosure Guidance and Transparency Rules.
James Barder, Futura's Chief Executive Officer, commented:
"Support from all our shareholders provides the company with
continued cash security from which to grow and look to the future
with confidence. I welcome today's announcement and the support
from Lombard Odier, as these funds provide Futura Medical with good
visibility into 2025 as the Company prepares for the next chapter
of growth with anticipated launches, and the scale up of
commercialisation of MED3000".
The information contained within this announcement is deemed by
the Company to constitute inside information as stipulated under
the Market Abuse Regulation (EU) No. 596/2014 as amended by The
Market Abuse (Amendment) (EU Exit) Regulations 2019. Upon the
publication of this announcement via the Regulatory Information
Service, this inside information is now considered to be in the
public domain.
-ENDS-
For further information please contact:
Futura Medical plc
James Barder, Chief Executive
Angela Hildreth, Finance Director and COO
Email: investor.relations@futuramedical.com
Tel: +44 (0) 1483 685 670
www.futuramedical.com
Nominated Adviser and Sole Broker:
Liberum
Phil Walker/ Richard Lindley/ Ben Cryer
Tel: +44 (0) 20 3100 2000
For media enquiries please contact:
Optimum Strategic Communications
Hollie Vile/ Jonathan Edwards/ Zoe Bolt
Email: futuramedical@optimumcomms.com
Tel: +44 (0) 203 882 9621
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCGPUGPQUPWUMP
(END) Dow Jones Newswires
June 12, 2023 03:23 ET (07:23 GMT)
Futura Medical (LSE:FUM)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Futura Medical (LSE:FUM)
Gráfica de Acción Histórica
De May 2023 a May 2024